Flecainide Initiation Protocol for Hospitalized Patients
For patients with sustained ventricular tachycardia (VT), flecainide must be initiated in-hospital with continuous rhythm monitoring, regardless of cardiac status. 1
Pre-Initiation Screening & Contraindications
Absolute Contraindications
- Structural heart disease: Left ventricular ejection fraction <40%, significant LV hypertrophy 2, 3
- Coronary artery disease: Active ischemia or history of myocardial infarction 2
- Advanced conduction disease: Second- or third-degree AV block, left bundle branch block, or right bundle branch block with left hemiblock 2
- Severe renal impairment: Creatinine clearance <35 mL/min/1.73 m² 1
- Severe hepatic impairment 2
Required Pre-Treatment Evaluation
- 12-lead ECG: Document baseline PR, QRS, and QTc intervals 2
- Echocardiogram: Assess LV function and exclude structural disease 2
- Ischemia assessment: For patients >50 years or with atherosclerotic risk factors, consider stress testing before initiation 2
- Renal function: Creatinine clearance calculation 1
- Electrolytes: Ensure normal potassium and magnesium 2
Dosing Regimens
For Paroxysmal Supraventricular Tachycardia (PSVT) and Paroxysmal Atrial Fibrillation (PAF)
- Starting dose: 50 mg every 12 hours 1
- Titration: Increase by 50 mg twice daily every 4 days until efficacy achieved 1
- Maximum dose: 300 mg/day 1
For Sustained Ventricular Tachycardia
- Starting dose: 100 mg every 12 hours 1
- Titration: Increase by 50 mg twice daily every 4 days 1
- Maximum dose: 400 mg/day (most patients controlled on ≤300 mg/day) 1
- Critical warning: Higher initial doses and rapid titration increase proarrhythmic events and heart failure, particularly in first few days 1
Renal Impairment Dosing
- Severe impairment (CrCl <35 mL/min): Start 100 mg once daily; requires frequent plasma level monitoring 1
- Moderate impairment: Start 100 mg every 12 hours; plasma monitoring recommended 1
- Dose adjustments: Make very cautiously after plasma levels plateau (>4 days) 1
Monitoring Requirements
In-Hospital Monitoring
Continuous cardiac monitoring is mandatory during initiation for sustained VT patients 1. For PSVT/PAF, guidelines support outpatient initiation only in patients without structural heart disease when the drug is well-tolerated 4, 5, though recent data show 3% adverse event rate even in selected patients 6.
ECG Monitoring Schedule
- Baseline ECG: Before first dose 2
- Post-initiation ECG: 48-72 hours after starting (outpatient) or daily (inpatient) 2
- Critical threshold: QRS widening >25% from baseline indicates increased proarrhythmia risk—reduce dose or discontinue 2
- PR interval: Monitor for excessive prolongation 2
Plasma Level Monitoring
- Therapeutic range: 0.2-1.0 mcg/mL (200-1000 ng/mL) 1
- Timing: Trough levels (within 1 hour pre-dose) at steady state (after ≥5 doses or 3-5 days) 1
- Mandatory monitoring: Severe renal failure, severe hepatic disease, concurrent amiodarone therapy 1
- Recommended monitoring: Heart failure, moderate renal disease 1
- Pediatric note: Plasma levels can increase rapidly despite stable dosing; small dose changes may cause disproportionate level increases 1
Concurrent AV Nodal Blockade
Class Ic agents must be combined with AV nodal-blocking agents (beta-blockers or non-dihydropyridine calcium channel blockers) to prevent 1:1 AV conduction if atrial fibrillation organizes into atrial flutter [2, @102@]. This is a strong recommendation with low-quality evidence 2.
Drug Interactions
Amiodarone
When flecainide is given with amiodarone, reduce the usual flecainide dose by 50% and monitor closely for adverse effects. Plasma level monitoring is strongly recommended 1.
Other Interactions
- Intravenous lidocaine has been used occasionally while awaiting flecainide effect; no adverse interactions reported, though formal studies lacking 1
Patient Counseling Instructions
For Staff
- Proarrhythmia risk: Highest during first few days of therapy; watch for new arrhythmias, syncope, or hemodynamic instability 1, 6
- Adverse events to monitor:
- All significant adverse events in recent study occurred with flecainide 300 mg or propafenone 600 mg doses 6
For Patients
- Common side effects: Dizziness (most frequent), blurred vision, difficulty focusing—usually mild, transient, and tolerable 7
- Serious symptoms requiring immediate attention: Syncope, severe dizziness, palpitations, chest pain, shortness of breath
- Long-term follow-up: Annual assessment for coronary artery disease symptoms; formal stress testing if symptoms develop 2
- Steady-state timing: Optimal effect may not be achieved for 2-3 days after starting or dose change due to 12-27 hour half-life 1
Special Populations
Heart Failure
Use cautiously in patients with history of heart failure or myocardial dysfunction 1. Flecainide is contraindicated in HFrEF (LVEF <40%) 2, 3.
Elderly
No specific dose adjustment required, but increased vigilance for adverse effects warranted.
Pregnancy/Lactation
Not addressed in provided guidelines; consult specialized resources.
Common Pitfalls
- Initiating without structural heart disease screening: Always obtain echocardiogram before starting 2
- Failing to add AV nodal blocker: Risk of rapid 1:1 flutter conduction 2
- Too-rapid titration in VT patients: Increases proarrhythmia and heart failure risk 1
- Ignoring QRS widening: >25% increase mandates dose reduction or discontinuation 2
- Inadequate renal function assessment: Severe renal impairment requires 50% dose reduction and mandatory plasma monitoring 1
- Using in post-MI or CAD patients: Contraindicated due to increased mortality risk 2